Michael Rockwell, MD
Psychiatry · Phoenix, AZNPI 1083655195
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 422 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 28.6% of the total. Among psychiatry clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 422 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Sunovion Pharmaceuticals Inc.$1K
- Alkermes, Inc.$455
- Takeda Pharmaceuticals U.S.A., Inc.$370
- Axsome Therapeutics, Inc.$317
- Otsuka America Pharmaceutical, Inc.$298
- plus $2K from 19 others
What the payments were for
- Food & beverage$6,78899%
- Education$771%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 152 | $1,964 |
| Sunovion Pharmaceuticals Inc. | 71 | $1,023 |
| Alkermes, Inc. | 20 | $455 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $370 |
| Axsome Therapeutics, Inc. | 13 | $317 |
| Otsuka America Pharmaceutical, Inc. | 17 | $298 |
| Lundbeck LLC | 17 | $295 |
| Neurocrine Biosciences, Inc. | 15 | $279 |
| Johnson & Johnson | 8 | $235 |
| Supernus Pharmaceuticals, Inc. | 11 | $227 |
| Teva Pharmaceuticals USA, Inc. | 12 | $212 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $199 |
| Bausch Health US, LLC | 8 | $149 |
| Corium, LLC | 7 | $140 |
| Eisai Inc. | 6 | $110 |
| Almatica Pharma LLC | 5 | $107 |
| Vanda Pharmaceuticals Inc. | 5 | $105 |
| Merck | 7 | $94 |
| Idorsia Pharmaceuticals US Inc | 5 | $89 |
| Shire North American Group Inc | 4 | $66 |
| Jazz Pharmaceuticals Inc. | 2 | $33 |
| Avanir Pharmaceuticals, Inc. | 2 | $31 |
| Tris Pharma Inc | 1 | $23 |
| Alfasigma USA, Inc. | 1 | $22 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,865 in reported general payments places this provider in the 90th percentile of 573 psychiatry providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $102,467 |
| VraylarCariprazine Hcl | 38 | $66,270 |
| TrintellixVortioxetine Hydrobromide | 46 | $39,282 |
| Vilazodone Hcl | 71 | $10,479 |
| Duloxetine Hcl | 363 | $7,164 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 227 | $6,861 |
| Lisdexamfetamine Dimesylate | 15 | $4,056 |
| DayvigoLemborexant | 11 | $3,789 |
| Quetiapine Fumarate | 214 | $3,784 |
| Lamotrigine | 244 | $3,556 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 29 | $3,308 |
| Bupropion XlBupropion Hcl | 85 | $3,012 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 104 | $2,927 |
| Bupropion Hcl SrBupropion Hcl | 111 | $2,816 |
| Trazodone Hcl | 300 | $2,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $279 | $102,46712 claims |
| AbbVieVraylar | $1,964 | $66,27038 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $370 | $39,28246 claims |
| Eisai Inc.Dayvigo | $110 | $3,78911 claims |
| Almatica Pharma LLCSertraline Hcl | $107 | $1,041160 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 573 psychiatry providers in Arizona.
Other psychiatry in Phoenix
- Jason CaplanPhoenix$999K
- Thomas GazdaPhoenix$714K
- Monica BenavidezPhoenix$435K
- Eric ReimanPhoenix$157K
- Padma AkingPhoenix$44K
- Ahmed ElmaadawiPhoenix$32K
- Amnon KahanePhoenix$18K
- Aaron ClayPhoenix$14K
- Joel ParkerPhoenix$11K
- Ivan EngelPhoenix$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.